Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma.
Pepsinogen C is an aspartyl protease mainly involved in the digestion of proteins in the stomach, and an androgen-inducible protein in breast cancer cells. The aims of this study were to evaluate the expression and clinical significance of this enzyme in the primary tumors of prostate cancer patients with bone metastasis who were scheduled to receive antiandrogenic therapy. This study was prospectively performed in 28 stage D2 prostate cancer patients who, after diagnosis, received maximum androgen blockade. Pepsinogen C tumor expression was analyzed in samples (24 from needle biopsy cylinders and four from transurethral resection specimens) from primary tumors using an immunohistochemical assay. Twelve prostate carcinomas (42.8%) were positive for pepsinogen C. Pepsinogen C was a significant prognostic factor to predict a longer overall survival in the patients of our study (p<0.01). Pepsinogen C can be a new prognostic factor and a useful biological marker of androgen dependency in prostate cancer.
Department of Urology, Hospital de Jove, Gijón, Spain.
M
M
Díaz
J C
JC
Rodríguez
J
J
Sánchez
M T
MT
Sánchez
A
A
Martín
A M
AM
Merino
F
F
Vizoso
D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens / Q000494:pharmacology; D015415:Biomarkers; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis; D020115:Pepsinogen C / Q000032:analysis*; D011379:Prognosis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality
D000728:Androgens; D015415:Biomarkers; D020115:Pepsinogen C